1
|
Liao D, Zhong L, Yin J, Zeng C, Wang X,
Huang X, Chen J, Zhang H, Zhang R, Guan XY, et al: Chromosomal
translocation-derived aberrant Rab22a drives metastasis of
osteosarcoma. Nat Cell Biol. 22:868–881. 2020.PubMed/NCBI View Article : Google Scholar
|
2
|
Fang Y and Fullwood MJ: Roles, functions,
and mechanisms of long non-coding RNAs in cancer. Genomics
Proteomics Bioinformatics. 14:42–54. 2016.PubMed/NCBI View Article : Google Scholar
|
3
|
Chen H, Xu Z and Liu D: Small non-coding
RNA and colorectal cancer. J Cell Mol Med. 23:3050–3057.
2019.PubMed/NCBI View Article : Google Scholar
|
4
|
Zhao W, Zhang D, Qin P, Zhang J, Cui X,
Gao J, Wang J and Li J: Long non-coding RNA EPIC1 inhibits
viability and invasion of osteosarcoma cells by promoting MEF2D
ubiquitylation. Int J Biol Macromol. 128:566–573. 2019.PubMed/NCBI View Article : Google Scholar
|
5
|
Wang J, Cao L, Wu J and Wang Q: Long
non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326
and promotes tumorigenesis in osteosarcoma. Int J Oncol. 52:77–88.
2018.PubMed/NCBI View Article : Google Scholar
|
6
|
Chen B and Huang S: Circular RNA: An
emerging non-coding RNA as a regulator and biomarker in cancer.
Cancer Lett. 418:41–50. 2018.PubMed/NCBI View Article : Google Scholar
|
7
|
Jin J, Chen A, Qiu W, Chen Y, Li Q, Zhou X
and Jin D: Dysregulated circRNA_100876 suppresses proliferation of
osteosarcoma cancer cells by targeting microRNA-136. J Cell
Biochem. 120:15678–15687. 2019.PubMed/NCBI View Article : Google Scholar
|
8
|
Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y,
Huang K, Wang G, Wang J, Ma J, et al: Circular RNA circTADA2A
promotes osteosarcoma progression and metastasis by sponging
miR-203a-3p and regulating CREB3 expression. Mol Cancer.
18(73)2019.PubMed/NCBI View Article : Google Scholar
|
9
|
Kun-Peng Z, Chun-Lin Z, Xiao-Long M and
Lei Z: Fibronectin-1 modulated by the long noncoding RNA
OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of
osteosarcoma cells. J Cell Physiol. 234:6927–6939. 2019.PubMed/NCBI View Article : Google Scholar
|
10
|
Kun-Peng Z, Chun-Lin Z, Jian-Ping H and
Lei Z: A novel circulating hsa_circ_0081001 act as a potential
biomarker for diagnosis and prognosis of osteosarcoma. Int J Biol
Sci. 14:1513–1520. 2018.PubMed/NCBI View Article : Google Scholar
|
11
|
Zhu KP, Ma XL and Zhang CL: LncRNA ODRUL
contributes to osteosarcoma progression through the miR-3182/MMP2
axis. Mol Ther. 25:2383–2393. 2017.PubMed/NCBI View Article : Google Scholar
|
12
|
Ma XL, Zhan TC, Hu JP, Zhang CL and Zhu
KP: Doxorubicin-induced novel circRNA_0004674 facilitates
osteosarcoma progression and chemoresistance by upregulating MCL1
through miR-142-5p. Cell Death Discov. 7(309)2021.PubMed/NCBI View Article : Google Scholar
|
13
|
Dai J, Xu L, Hu X, Han G, Jiang H, Sun H,
Zhu G and Tang X: Long noncoding RNA OIP5-AS1 accelerates CDK14
expression to promote osteosarcoma tumorigenesis via targeting
miR-223. Biomed Pharmacother. 106:1441–1447. 2018.PubMed/NCBI View Article : Google Scholar
|
14
|
Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang
Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1
causes cisplatin resistance in osteosarcoma through inducing the
LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
J Cell Biochem. 120:9656–9666. 2019.PubMed/NCBI View Article : Google Scholar
|
15
|
Almeida E, Mascarenhas BA, Cerqueira A and
Medrado AR: Chondroblastic osteosarcoma. Oral Maxillofac Pathol.
18:464–468. 2014.PubMed/NCBI View Article : Google Scholar
|
16
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini
G, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide,
high-dose methotrexate, cisplatin, and doxorubicin for patients
with localized osteosarcoma of the extremity: A joint study by the
Italian and Scandinavian sarcoma groups. J Clin Oncol.
23:8845–8852. 2005.PubMed/NCBI View Article : Google Scholar
|
17
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-Year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006.PubMed/NCBI View Article : Google Scholar
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
19
|
Miwa S, Shirai T, Yamamoto N, Hayashi K,
Takeuchi A, Igarashi K and Tsuchiya H: Current and emerging targets
in immunotherapy for osteosarcoma. J Oncol.
2019(7035045)2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Bacci G, Mercuri M, Briccoli A, Ferrari S,
Bertoni F, Donati D, Monti C, Zanoni A, Forni C and Manfrini M:
Osteogenic sarcoma of the extremity with detectable lung metastases
at presentation. Results of treatment of 23 patients with
chemotherapy followed by simultaneous resection of primary and
metastatic lesions. Cancer. 79:245–254. 1997.PubMed/NCBI
|
21
|
Brooks JD: Translational genomics: The
challenge of developing cancer biomarkers. Genome Res. 22:183–187.
2012.PubMed/NCBI View Article : Google Scholar
|
22
|
Xiao H, Zhang F, Zou Y, Li J, Liu Y and
Huang W: The function and mechanism of long non-coding RNA-ATB in
cancers. Front Physiol. 9(321)2018.PubMed/NCBI View Article : Google Scholar
|
23
|
Smolle MA, Prinz F, Calin GA and Pichler
M: Current concepts of non-coding RNA regulation of immune
checkpoints in cancer. Mol Aspects Med. 70:117–126. 2019.PubMed/NCBI View Article : Google Scholar
|
24
|
Wang Y, Zeng X, Wang N, Zhao W, Zhang X,
Teng S, Zhang Y and Lu Z: Long noncoding RNA DANCR, working as a
competitive endogenous RNA, promotes ROCK1-mediated proliferation
and metastasis via decoying of miR-335-5p and miR-1972 in
osteosarcoma. Mol Cancer. 17(89)2018.PubMed/NCBI View Article : Google Scholar
|
25
|
Liu R, Zhang C, Hu Z, Li G, Wang C, Yang
C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA
signature identified from genome-wide serum microRNA expression
profiling serves as a fingerprint for gastric cancer diagnosis. Eur
J Cancer. 47:784–791. 2011.PubMed/NCBI View Article : Google Scholar
|
26
|
Ren HY, Sun LL, Li HY and Ye ZM:
Prognostic significance of serum alkaline phosphatase level in
osteosarcoma: A meta-analysis of published data. Biomed Res Int.
2015(160835)2015.PubMed/NCBI View Article : Google Scholar
|
27
|
Marais LC, Bertie J, Rodseth R, Sartorius
B and Ferreira N: Pre-treatment serum lactate dehydrogenase and
alkaline phosphatase as predictors of metastases in extremity
osteosarcoma. J Bone Oncol. 4:80–84. 2015.PubMed/NCBI View Article : Google Scholar
|
28
|
Yotsukura S and Mamitsuka H: Evaluation of
serum-based cancer biomarkers: A brief review from a clinical and
computational viewpoint. Crit Rev Oncol Hematol. 93:103–115.
2015.PubMed/NCBI View Article : Google Scholar
|